Poseidon signed a cooperation agreement with a leading dermatology hospital to conduct real-world evidence studies of our anti-IL-23 monoclonal antibody NVP-601 in psoriasis, collecting efficacy and safety data from routine clinical practice in China.
The RWE program plans to enroll over 2,000 patients with moderate-to-severe plaque psoriasis, with two-year follow-up across heterogeneous populations.
NVP-601 previously demonstrated PASI 90 response rates above 80% in Phase III trials, with its NDA under review.